Analysts Expect Encompass Health Co. (NYSE:EHC) Will Announce Quarterly Sales of $1.36 Billion

Brokerages expect that Encompass Health Co. (NYSE:EHC – Get Rating) will post $1.36 billion in sales for the current quarter, Zacks reports. Five analysts have provided estimates for Encompass Health’s earnings, with estimates ranging from $1.35 billion to $1.37 billion. Encompass Health posted sales of $1.29 billion in the same quarter last year, which suggests a positive year over year growth rate of 5.4%. The company is expected to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Encompass Health will report full-year sales of $5.46 billion for the current financial year, with estimates ranging from $5.44 billion to $5.47 billion. For the next financial year, analysts expect that the company will post sales of $5.90 billion, with estimates ranging from $5.79 billion to $6.00 billion. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Encompass Health.

Encompass Health (NYSE:EHC – Get Rating) last posted its quarterly earnings data on Wednesday, April 27th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The business had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.32 billion. Encompass Health had a return on equity of 17.99% and a net margin of 7.51%. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.05 earnings per share.

EHC has been the subject of a number of analyst reports. Raymond James decreased their price objective on Encompass Health from $90.00 to $80.00 and set a “strong-buy” rating for the company in a research note on Monday, February 7th. StockNews.com raised Encompass Health from a “hold” rating to a “buy” rating in a report on Thursday, May 12th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Encompass Health from $95.00 to $80.00 in a research note on Thursday, January 20th. Zacks Investment Research raised shares of Encompass Health from a “sell” rating to a “hold” rating and set a $76.00 price objective on the stock in a research report on Monday, April 11th. Finally, Truist Financial upped their target price on shares of Encompass Health from $78.00 to $85.00 in a report on Thursday, April 7th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $83.89.

In other Encompass Health news, Director Kevin J. O’connor purchased 1,000 shares of Encompass Health stock in a transaction that occurred on Friday, May 6th. The shares were bought at an average price of $66.48 per share, for a total transaction of $66,480.00. Following the acquisition, the director now directly owns 3,436 shares in the company, valued at $228,425.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.70% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Whittier Trust Co. acquired a new position in Encompass Health in the 4th quarter valued at about $26,000. Meeder Asset Management Inc. acquired a new position in Encompass Health in the 1st quarter valued at $33,000. Signaturefd LLC grew its position in Encompass Health by 58.9% in the fourth quarter. Signaturefd LLC now owns 499 shares of the company’s stock valued at $33,000 after acquiring an additional 185 shares in the last quarter. Parallel Advisors LLC increased its stake in Encompass Health by 103.1% during the 4th quarter. Parallel Advisors LLC now owns 532 shares of the company’s stock worth $35,000 after buying an additional 270 shares during the period. Finally, Worth Asset Management LLC acquired a new position in Encompass Health during the 1st quarter valued at about $35,000. Hedge funds and other institutional investors own 91.70% of the company’s stock.

NYSE:EHC opened at $64.05 on Friday. The company has a market cap of $6.39 billion, a price-to-earnings ratio of 16.38, a PEG ratio of 2.14 and a beta of 0.95. The company has a debt-to-equity ratio of 1.32, a current ratio of 1.26 and a quick ratio of 1.26. The stock’s 50 day simple moving average is $68.72 and its two-hundred day simple moving average is $65.96. Encompass Health has a 1 year low of $56.31 and a 1 year high of $87.75.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 20th. Stockholders of record on Wednesday, July 13th will be paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 1.75%. The ex-dividend date is Tuesday, July 12th. Encompass Health’s dividend payout ratio (DPR) is presently 28.64%.

About Encompass Health (Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Read More